BCRP/ABCG2 is involved in the determination of sorafenib sensitivity in Hep3B hepatocellular carcinoma (HCC) cells.

<p>(A–B) Hep3B cells were either knocked down with BCRP siRNA (A) or transfected with Flag-BCRP expression vector (B). One day later, cells were re-seeded at the same density, followed by treatment of 5 µM sorafenib. Three-to five days later, cell viability was measured by using bright-field imaging (<i>top panel</i>) and crystal violet staining assay (<i>middle panel</i>). BCRP/ABCG2 expression was detected by Western blot analysis (<i>bottom panel</i>).